Clinical Trial Detail

NCT ID NCT02796352
Title A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ahmad Tarhini
Indications

melanoma

Therapies

Aldesleukin

Age Groups: adult senior

No variant requirements are available.